12 Months of Itraconazole Is Superior to Six Months for Preventing Relapses of Chronic Pulmonary Aspergillosis
A randomized, controlled clinical trial from India found a significant reduction in relapses of chronic pulmonary aspergillosis in patients treated with itraconazole for 12 months compared to those treated for six months. There were more adverse events in the patients treated for 12 months.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.